The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content


The United States Food & Drug Administration (FDA) is warning consumers that the prescription weight loss drug Belviq may cause cancer. A clinical trial showed an increased risk of cancer — and Eisai Inc., the manufacturer, has requested to voluntarily withdraw the drug from the market.

Belviq was approved by the FDA in 2012 to help overweight and obese adults lose weight. Belviq works by increasing feelings of fullness. Eisai, Inc., conducted a randomized double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. The study showed that approximately 12,000 participants who took the medication over a period of 5 years, more patients taking Belviq (Locaserin) were diagnosed with cancer. Pancreatic, colorectal and lung cancer occurred more frequently among patients taking Belviq.  

If you or a loved one has suffered from cancer from taking Belviq, please call the experts at Inserra Kelley Sewell to see whether you might be entitled to compensation.  

Comments for this article are closed.